View Exam | PowerPak

1. For which of the following genes should gene expression loss testing be performed to support the diagnosis of epithelioid sarcoma (ES)?

A. VEGFR B. TP53 C. INI1 D. EGFR

2. Enhancer of zeste homolog 2 (EZH2)-targeted therapies act to affect which part of the epigenetic pathway to promote an open chromatin state?

A. DNA methyltransferase B. Histone acetyltransferase C. Isocitrate dehydrogenase D. Polycomb repressive complex 2

3. Based on data from a phase 2 international, open-label, basket study, which of the following treatments is preferred, showing a median overall survival of 19 months and a median progression-free survival of 5.5 months?

A. Trabectedin B. Tazemetostat C. Pazopanib D. Doxorubicin

4. Your patient is a 42-year-old woman presenting with metastatic ES who has progressed on single-agent doxorubicin. You advise the care team to begin tazemeostat, but also see that she is currently taking a moderate CYP3A4 inhibitor for which the dose cannot be adjusted or discontinued. How would you approach the team about dosing recommendations for tazemetostat for this patient?

A. A dose adjustment is needed for tazemetostat; begin tazemetostat at 200 mg by mouth (PO) twice daily (BID) B. A dose adjustment is needed for tazemetostat; begin tazemetostat at 400 mg PO BID C. A dose adjustment is needed for tazemetostat; begin tazemetostat at 600 mg PO BID D. No dose adjustment is needed for tazemetostat; begin tazemetostat at 800 mg PO BID

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. For which of the following genes should gene expression loss testing be performed to support the diagnosis of epithelioid sarcoma (ES)?

2. Enhancer of zeste homolog 2 (EZH2)-targeted therapies act to affect which part of the epigenetic pathway to promote an open chromatin state?

3. Based on data from a phase 2 international, open-label, basket study, which of the following treatments is preferred, showing a median overall survival of 19 months and a median progression-free survival of 5.5 months?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. For which of the following genes should gene expression loss testing be performed to support the diagnosis of epithelioid sarcoma (ES)?

2. Enhancer of zeste homolog 2 (EZH2)-targeted therapies act to affect which part of the epigenetic pathway to promote an open chromatin state?

3. Based on data from a phase 2 international, open-label, basket study, which of the following treatments is preferred, showing a median overall survival of 19 months and a median progression-free survival of 5.5 months?

« Return to Activity

Customers who Purchased
this Activity also Purchased